Cambridge Healthtech Institute’s 4th Annual

Lead Generation Strategies

Small Molecule Hits to Quality Drug Leads via Biophysical and Other New Approaches

September 17-18, 2020


This conference focuses on how discovery chemists choose which compounds to optimize into drug leads from the many small-molecule compounds that arise from combining newer hit-finding strategies, such as encoded libraries, fragment-based drug design (FBDD), and biophysical screening approaches with classical high-throughput screens. Drug discovery colleagues from pharma, biotech, and academia convene to share new biophysical techniques and discuss applying orthogonal approaches for more efficient and successful ‘hit to lead’ drug development endeavors.

Preliminary Agenda


Innovations in Label-Free Biosensing for Meeting the Challenges of Increasingly Diverse Chemical Matter

John Quinn, Biophysical Group, Biochemical and Cellular Pharmacology, Genentech

Degrader-Induced Ternary Complex Modeling

Scott Eron, PhD, Research Scientist II, Biochemistry, Biophysics & Crystallography, C4 Therapeutics, Inc.


High-Throughput Virtual Screening for Discovery of Novel and Selective Allosteric Inhibitors of Human EAAT2

Marie-Laure Rives, PhD, Principal Scientist, Molecular and Cellular Pharmacology, Discovery Sciences, Janssen, the Pharmaceutical Companies of Johnson & Johnson

From DNA-Encoded Library Hits to Drug Leads: A Case Study

Christopher Phelps, PhD, Director, Medicinal Science and Technology, GlaxoSmithKline

Leveraging the Power of HTS to Define a Hit Series 

Nava Krishnan, PhD, Senior Scientist, Drug Discovery Science & Technology, Abbvie


Talk Title to be Announced

Beth Knapp-Reed, PhD, Scientific Leader, NCE-MD Medicinal Chemistry, R&D, Platform Technology & Science, GSK

Fast NMR Structure Determination of Protein-Fragment Complexes

Julien Orts, PhD, Assistant Professor, Laboratory of Physical Chemistry, Swiss Federal Institute of Technology, ETH


Combining Biophysical Approaches for Lead Generation: Case Studies

Pedro Serrano, PhD, Head, Structural Biology & Biophysics, Takeda San Diego

Characterization of Novel STING Ligands Using SPR and Orthogonal Approaches

Gottfried Schroeder, PhD, Senior Scientist, Department of Pharmacology, Merck Research Labs – Boston

Tools for the Discovery of KRAS Pathway Inhibitors

Ekaterina Kuznetsova, PhD, Director, Product Development, Reaction Biology

Using Smart Drug Discovery Software to Enhance Collaboration and Manage Assay Data

Robert Thorn, PhD, Customer Engagement Scientist, Collaborative Drug Discovery

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252



For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286